{"analyses":[{"ciLowerLimit":"0.79","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.53","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","otherAnalysisDescription":"Reference level = placebo arm","pValue":"0.289","paramType":"Cox Proportional Hazard","paramValue":"1.10","statisticalComment":"One-sided test","statisticalMethod":"Gray's test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.8","upperLimit":"19.3","value":"15.3"},{"groupId":"OG001","lowerLimit":"14.0","upperLimit":"22.1","value":"17.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"376"},{"groupId":"OG001","value":"384"}],"units":"Participants"}],"description":"Non-prostate cancer death rates were estimated by the cumulative incidence method, with failure defined as any death that does not fall into the following categories: death due to prostate cancer or complications of protocol treatment (centrally reviewed), death with known progressive metastatic disease while on salvage hormone therapy, or death with a known rising PSA while on salvage hormone therapy. All other deaths are considered competing risks. Patients alive at time of analysis were censored. Any other death was treated as a competing risk. Four-year follow-up was required of all patients, but twelve-year rates were reported.\n\nPatients are followed until death. \"Non-Prostate cancer death\" is a more accurate wording for the protocol endpoint of \"non-disease-specific survival\", and matches the protocol definition.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy (64.8 Gy) + placebo (daily 2 years)","id":"OG000","title":"Placebo"},{"description":"Radiation therapy (64.8 Gy) + bicalutamide (150 mg daily 2 years)","id":"OG001","title":"Bicalutamide"}],"paramType":"NUMBER","populationDescription":"Eligible patients who did not withdraw consent.","reportingStatus":"POSTED","timeFrame":"From date of randomization to 12 years.","title":"Non-Prostate Cancer Death (12-year Rates Reported)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}